PACIRA BIOSCIENCES, INC. Current State and Local Tax Expense (Benefit)
PACIRA BIOSCIENCES, INC. (PCRX) reported Current State and Local Tax Expense (Benefit) of $1.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentStateAndLocalTaxExpenseBenefit · last filed 2026-02-26
- PACIRA BIOSCIENCES, INC. current state and local tax expense (benefit) for the quarter ending 2020-12-31 was $226.00K, a 83.22% decline year-over-year.
- PACIRA BIOSCIENCES, INC. current state and local tax expense (benefit) for the quarter ending 2020-09-30 was $603.00K, a 122.51% increase year-over-year.
- PACIRA BIOSCIENCES, INC. current state and local tax expense (benefit) for the quarter ending 2019-12-31 was $1.35M.
- PACIRA BIOSCIENCES, INC. current state and local tax expense (benefit) for the quarter ending 2019-09-30 was $271.00K.
- PACIRA BIOSCIENCES, INC. current state and local tax expense (benefit) for fiscal 2025 was $1.50M, a 77.10% decline from fiscal 2024.
- PACIRA BIOSCIENCES, INC. current state and local tax expense (benefit) for fiscal 2024 was $6.53M, a 167.06% increase from fiscal 2023.
- PACIRA BIOSCIENCES, INC. current state and local tax expense (benefit) for fiscal 2023 was $2.44M, a 53.96% decline from fiscal 2022.
- PACIRA BIOSCIENCES, INC. current state and local tax expense (benefit) for fiscal 2022 was $5.31M, a 50.27% increase from fiscal 2021.
| Period end | Current State and Local Tax Expense (Benefit) 3 month | Current State and Local Tax Expense (Benefit) 6 month | Current State and Local Tax Expense (Benefit) 9 month | Current State and Local Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.50M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $6.53M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $2.44M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $5.31M 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $3.53M 10-K · filed 2024-02-29 | |||
| 2020-12-31 | $226.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $829.00K derived: sum of 2 quarters · filed 2023-02-28 | $1.19M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $603.00K 10-Q · filed 2020-10-30 | $959.00K 10-Q · filed 2020-10-30 | ||
| 2019-12-31 | $1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.62M derived: sum of 2 quarters · filed 2022-02-28 | $2.10M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $271.00K 10-Q · filed 2020-10-30 | $749.00K 10-Q · filed 2020-10-30 | ||
| 2018-12-31 | $142.00K 10-K · filed 2021-03-01 | |||
| 2017-12-31 | $140.00K 10-K · filed 2020-02-21 | |||
| 2016-12-31 | $94.00K 10-K · filed 2019-02-28 | |||
| 2015-12-31 | $172.00K 10-K · filed 2018-02-28 | |||
| 2014-12-31 | $173.00K 10-K · filed 2017-03-01 | $173.00K 10-K · filed 2016-02-25 | ||
| 2013-12-31 | -$442.00K 10-K · filed 2016-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |